Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Net Income
Bottom-line profit after all expenses, interest, and taxes.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$24.15M, compared with -$52.2M a year earlier. Trailing-twelve-month net income was -$246.41M.
Context
- Net income amounted to 762355.6% of revenue in FY2025, up 200070.3 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$115.38M (+58.0%) for the fiscal year ending Dec 2026, a step up from the +20.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.15M+82.8% QoQ
- Last fiscal yearDec 2025
- -$274.45M+20.0% YoY
- LTMMar 2026
- -$246.41M+26.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +53.7% | -8.8% | -62.5 pp |
| 1 year | +20.0% | +58.0% | +38.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (274.45M) USD
- Year-over-year change
- +20.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (274.45M) | +20.0% |
| FY2024 | 2024-12-31 | (342.99M) | -46.2% |
| FY2023 | 2023-12-31 | (234.63M) | -28.1% |
| FY2022 | 2022-12-31 | (183.12M) | +26.8% |
| FY2021 | 2021-12-31 | (250.22M) | — |
Net Income vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +26.3% is the 5th highest of 10, against a peer median of -7.6%.
- Net income amounts to 794858.1% of revenue for LYEL, versus a peer median of 1788.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$27.37M USD | +52.6% | — | — | |
GNLXGenelux Corporation | LTM Mar 2026 | -$31.78M USD | -7.7% | — | 397225.0% |
| LTM Mar 2026 | -$33.61M USD | +61.8% | — | 15.6% | |
| LTM Mar 2026 | -CHF 66.22M CHF | -27.1% | — | 1788.8% | |
| LTM Mar 2026 | -$85.17M USD | — | — | 9243.0% | |
| LTM Mar 2026 | -$108.95M USD | +56.6% | — | 281.6% | |
| LTM Mar 2026 | -$156.4M USD | -7.6% | — | — | |
| LTM Mar 2026 | -$166.01M USD | -74.3% | — | — | |
| LTM Mar 2026 | -$173.76M USD | +31.1% | — | — | |
| LTM Mar 2026 | -$175.43M USD | -38.4% | — | — | |
| LTM Mar 2026 | -$246.41M USD | +26.3% | — | 794858.1% | |
| Peer median (excluding LYEL) | — | -7.6% | — | 1788.8% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.65M | 84.68M | 130K | 61K | 36K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.54M |
| Gross Profit | 10.65M | 84.68M | 130K | 61K | (11.5M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| Research & Development | 138.69M | 159.19M | 182.95M | 171.6M | 158.68M |
| Selling, General & Admin | 89.06M | 117.31M | 66.98M | 52.04M | 45.14M |
| Operating Expenses | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M |
| Depreciation & Amortization | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M |
| EBITDA | (236.6M) | (165.1M) | (214.38M) | (200.64M) | (262.91M) |
| EBITDA Margin | -2221.5% | -195.0% | -164909.2% | -328923.0% | -730302.8% |
| Operating Income | (214.78M) | (187.06M) | (247.01M) | (358.76M) | (203.77M) |
| Operating Margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| Interest Income | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (35.44M) | 3.94M | 12.38M | 15.76M | (70.67M) |
| Income Before Tax | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Pre-Tax Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Net Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (Basic) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| EPS (Diluted) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| Weighted Avg Shares | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
| Weighted Avg Shares (Diluted) | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.